ZVRA

BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two posters featuring long-term real-world data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium. "These presentations further expand the growing body of evidence supporting the long-term safety and effectiveness of arimoclomol in NPC," said Caroline Hastings, MD, Professor of Pediatrics, UCSF Benioff Children’s Hospital Oak

BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 92,200 shares of the Company’s common stock (the "Inducement Awards") to four new employees pursuant to the Company’s 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee’s start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee’s continued empl

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

SCHEDULE 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

10-Q - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2 million Company to host conference call and webcast TODAY, August 5, 2026, at 4:30 p.m. ET BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today reported its financial results for the second quarter ended June 30, 2026. "Zevra delivered strong MIPLYFFA performance and further established the therapy as an important treatment op

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra’s executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 11:00 a.m. ET. Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra’s website at investors.zevra.com. About Zevra Therape

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the publication of "Long-term real-world safety and effectiveness of arimoclomol in individuals with NPC: Outcomes from the US Early Access Program over a 4-year period" in Molecular Genetics and Metabolism. The longitudinal study evaluated arimoclomol in a broad US NPC population spanning a wide range of ages and disease severity, generating up to four years of follow-up data from routine clinical practice. The study includes the first published real-world da

Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access Program BOSTON, July 24, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion regarding the Marketing Authorization Application (MAA) for arimoclomol for the treatment of Niemann-Pick disease type C (NP

BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the second quarter on Wednesday, August 5, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the "Events & Presentations" page in the Investor Relations section of Zevra’s website at investors.zevra.com. To join via telephone, please use the following dial-in information: (800) 274-

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

BOSTON, June 23, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced the publication of "Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label pediatric substudy" in Molecular Genetics and Metabolism Reports. This multicenter, open-label pediatric substudy evaluated arimoclomol, in addition to concomitant miglustat, in five children with Niemann-Pick disease type C (NPC) aged 12 to <24 months at enrollment, assessing safety, tolerability, and pharmacokinetics over up to 36 months of treatment.

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, announced today that its Chief Medical Officer ("CMO") Adrian Quartel, M.D., FFPM, will be stepping down from his position due to personal reasons, effective July 3, 2026. Dr. Quartel will continue to support Zevra in a consulting capacity through December 31, 2026, while the Company conducts a search for its next CMO and ensures a seamless transition. "On behalf of everyone at Zevra, we are grateful for the role Adrian played in advancing our mission and positioning us for s

MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041 Separately filed patent term extension remains pending with the U.S. Patent and Trademark Office BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that it has submitted U.S. Patent No. 11,707,456 for MIPLYFFA® (arimoclomol) to the U.S. Food and Drug Administration for listing in the publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The patent expires on November 19,

8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 33,000 shares of the Company's common stock (the "Inducement Awards") to four new employees pursuant to the Company's 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee's continued employment o

4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)